Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 31 of the 57 sources its claims cite were checked for support.

Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial

Open access

Abstract

BACKGROUND: Prompt, effective treatment of confirmed malaria cases with artemisinin-based combination therapy (ACT) is a cornerstone of malaria control. Maximizing adherence to ACT medicines is key to ensuring treatment effectiveness. METHODS: This open-label, randomized trial evaluated caregiver adherence to co-formulated artemether-lumefantrine (AL) and fixed-dose amodiaquine-artesunate (AQAS) in Sierra Leone. Children aged 6-59 months diagnosed with malaria were recruited from two public clinics, randomized to receive AL or AQAS, and visited at home the day after completing treatment. Analyses were stratified by site, due to differences in participant characteristics and outcomes. RESULTS: Of the 784 randomized children, 680 (85.6%) were included in the final per-protocol analysis (340 AL, 340 AQAS). Definite adherence (self-reported adherence plus empty package) was higher for AL than AQAS at both sites (Site 1: 79.4% AL vs 63.4% AQAS, odds ratio [OR] 2.16, compared to probable adherence plus probable or definite non-adherence, 95% confidence interval [CI] 1.34-3.49; p = 0.001; Site 2: 52.1% AL vs 37.5% AQAS, OR 1.53, 95% CI 1.00-2.33, p = 0.049). However, self-reported adherence (ignoring drug package inspection) was higher for both regimens at both sites and there was no strong evidence of variation by treatment (Site 1: 96.6% AL vs 95.9% AQAS, OR 1.19, 95% CI 0.39-3.63, p = 0.753; Site 2: 91.5% AL vs 96.4% AQAS, OR 0.40, 95% CI 0.15-1.07, p = 0.067). In Site 2, correct treatment (correct dose + timing + duration) was lower for AL than AQAS (75.8% vs 88.1%, OR 0.42, 95% CI 0.23-0.76, p = 0.004). In both sites, more caregivers in the AQAS arm reported adverse events (Site 1: 3.4% AL vs 15.7% AQAS, p < 0.001; Site 2: 15.2% AL vs 24.4% AQAS, p = 0.039). CONCLUSIONS: Self-reported adherence was high for both AL and AQAS, but varied by site. These results suggest that each regimen has potential disadvantages that might affect adherence; AL was less likely to be taken correctly at one site, but was better tolerated than AQAS at both sites. Measuring adherence to anti-malarials remains challenging, but important. Future research should focus on comparative studies of new drug regimens, and improving the methodology of measuring adherence. TRIAL REGISTRATION: Clinicaltrials.gov, NCT01967472. Retrospectively registered 18 October 2013, https://clinicaltrials.gov/ct2/show/NCT01967472.

Overview

CoChat Summary

## TL;DR

This open-label randomized trial in Sierra Leone compared caregiver adherence to co-formulated artemether–lumefantrine (AL) versus fixed-dose amodiaquine–artesunate (AQAS) in children aged 6–59 months. Self-reported adherence was high for both regimens, but package-based adherence and correct treatment varied by site, with AL better on definite adherence and AQAS better on correct treatment at one site.

## Key findings

  • Of 784 randomized children, 680 (85.6%) were included in the final per-protocol analysis: 340 in the AL group and 340 in the AQAS group.
  • Definite adherence was higher for AL than AQAS at both sites:
  • Site 1: 79.4% AL vs 63.4% AQAS, OR 2.16, 95% CI 1.34–3.49, p = 0.001
  • Site 2: 52.1% AL vs 37.5% AQAS, OR 1.53, 95% CI 1.00–2.33, p = 0.049
  • Self-reported adherence was >90% for both regimens and showed no strong evidence of treatment differences:
  • Site 1: 96.6% AL vs 95.9% AQAS, p = 0.753
  • Site 2: 91.5% AL vs 96.4% AQAS, p = 0.067
  • In Site 2, correct treatment was lower for AL than AQAS: 75.8% vs 88.1%, OR 0.42, 95% CI 0.23–0.76, p = 0.004. More caregivers in the AQAS arm reported adverse events at both sites (Site 1: 3.4% vs 15.7%; Site 2: 15.2% vs 24.4%).

## Methods

  • Open-label, randomized trial conducted at two government-run outpatient facilities in Freetown, Sierra Leone, among children aged 6–59 months with positive malaria RDTs.
  • Children were randomized to AL or AQAS and visited at home the day after treatment completion; 784 were randomized, and analyses were stratified by site.
  • Primary adherence outcomes were based on self-report plus package inspection, recoded into self-reported adherence and package-based adherence; analyses used per-protocol as the main approach and compared results with intention-to-treat.

## Limitations

  • The paper states that adherence measures were limited by bias: self-report is subject to social desirability bias, and package inspection depends on whether packaging is retained.
  • The authors state that participant, caregiver, and household characteristics differed substantially between the two sites, so results were stratified by site; they note this variability may influence adherence.
  • The paper states that exclusions after randomization and incorrect treatment allocation were unexpectedly frequent, especially at Site 2, though sensitivity analyses found ITT and per-protocol results were almost identical.
  • Evident from the text: the study was open-label and participants/providers were not blinded, and home visits could have altered behavior, both of which may have inflated adherence estimates.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12936-018-2370-x

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Map of the study area. Blue dots—study sites
Fig. 1 Map of the study area. Blue dots—study sitesCC BY · PubMed Central
Fig. 2 Study profile. RDT, rapid diagnostic test; AQAS, fixed-dose combination amodiaquine–artesunate; AL, artemether–lumefantrine; SAE, serious adverse event
Fig. 2 Study profile. RDT, rapid diagnostic test; AQAS, fixed-dose combination amodiaquine–artesunate; AL, artemether–lumefantrine; SAE, serious adverse eventCC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 1 Not valid · 9 Not checked · 62 Own results and interpretations

26 more claims

Create a free account to see all 84 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 29

Create a free account to see these claims.

Citations

Cites

Show all 62 references

Research works printed but not linked: 8

  1. WHO. T3: test, treat, track initiative. Geneva: World Health Organization; 2012.
  2. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
  3. National Malaria Control Programme (NMCP). Guidelines for case management of malaria. Freetown: Government of Sierra Leone Ministry of Health and Sanitation; 2015.
  4. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.
  5. Sierra Leone Ministry of Health and Sanitation. Guidelines for case management of malaria in Sierra Leone. 3rd ed. Freetown: Sierra Leone Ministry of Health and Sanitation; 2010.
  6. WHO. World Malaria Report 2016. Geneva: World Health Organization; 2017.
  7. Novartis. Coartem monograph. vol. 4th ed. Basel: Novartis Pharma AG; 2005.
  8. Drugs for Neglected Diseases Initiative (DNDi). Press Pack for ASAQ. 2007.

Cited by

See all 26

Metadata

Authors
Banek, K., Webb, E. L., Smith, S. J., Chandramohan, D., & Staedke, S. G.
Affiliations
  • London School of Hygiene & Tropical Medicine (GB)
  • Ministry of Health and Sanitation (SL)
Corresponding author
Banek, Kristin
Venue
Malaria Journal
Published
2018-06-04
Volume
17
Issue
1
Pages
222-222
ISSN
1475-2875 (ISSN-L)
OpenAlex
W2806362238
Cited by
25
References
62
Citations by year
2026: 2 · 2023: 3 · 2022: 3 · 2021: 12 · 2020: 3 · 2019: 2
FWCI
3.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Malaria Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • American Association of University Women
  • Medical Research Council (MR/K012126/1)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
medication adherence, artemether-lumefantrine, uncomplicated malaria, pediatric malaria, artemisinin-based combination therapy, fixed-dose combination, self-reported adherence, caregiver adherence, Sierra Leone
MeSH terms
Artemether, Lumefantrine Drug Combination, Amodiaquine, Antimalarials, Child, Child, Preschool, Drug Combinations, Female, Humans, Infant, Malaria, Male, Patient Compliance, Retrospective Studies, Sierra Leone, Artemisinins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial. https://app.cochat.ai/papers/10.1186/s12936-018-2370-x
The paper
Banek, K., Webb, E. L., Smith, S. J., Chandramohan, D., & Staedke, S. G. (2018). Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial. Malaria Journal. https://doi.org/10.1186/s12936-018-2370-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.